HQ Function

Served as the primary hub for corporate operations, research and development strategy, clinical trial management, and business development activities before its acquisition by GSK.

Notable Features:

Located in a modern office park in the San Francisco Bay Area, providing access to a rich biotech ecosystem. The facility was typical of leased office spaces for biopharmaceutical companies of its size.

Work Culture:

Reported to have a focused, science-driven, and collaborative work culture, characteristic of late-stage biotech companies. Employees were dedicated to advancing treatments for patients with rare cancers and addressing unmet medical needs.

HQ Significance:

The San Mateo headquarters was central to Sierra Oncology's operations during its critical phase of developing momelotinib, navigating global clinical trials, and preparing for regulatory approval and commercialization, ultimately leading to its acquisition by GSK.

Values Reflected in HQ: The headquarters likely embodied values of innovation, patient-centricity, scientific rigor, and urgency, crucial for a company developing novel cancer therapies for underserved patient populations.

Location:

Prior to its acquisition by GSK, Sierra Oncology's global presence was primarily defined by its extensive clinical trial programs for momelotinib. These trials were conducted across numerous sites in North America (USA and Canada), Europe (various countries), and the Asia-Pacific region (e.g., Australia). The company was actively preparing for global commercialization, engaging with regulatory authorities in key markets worldwide.

Street Address:

1820 Gateway Drive, Suite 110

City:

San Mateo

State/Province:

CA

Country:

USA